Skip to main content
NIH funding notice PAR-22-084

Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)

Closed on November 16, 2024.

Posted
January 21, 2022
Close date
November 16, 2024
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $426,425 in first-year total cost, median $426,425.

Most frequent study sections

  1. Cancer Prevention Study Section[CPSS]1

Most frequent institutions

  1. BAYLOR COLLEGE OF MEDICINE1
Competing awards under PAR-22-084 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024CROSSTALK BETWEEN GUT MICROBIOTA AND HEPATOCELLULAR CARCINOMA INDUCED BY METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE1R21CA293626-01JALAL, PRASUN KUMARBAYLOR COLLEGE OF MEDICINE, TX$426,425CPSS

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-22-084: Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed) | ScienceDex | ConductScience